Interview with Jürgen Fritze, Head of Medical Affairs, PKV
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Address: Pascalstraße 6
52076 Aachen-Oberforstbach
Germany
Tel: 0.000357327771660262
Web: http://www.grunenthal.de/grt-web/Grunenthal_GmbH_Deutschland/136701132.jsp
Grünenthal is passionate about globally being the preferred partner in pain management for patients, health-care-professionals and payors. The corporation drives innovation to expand European market leadership in moderate to severe pain. Grünenthal is an independent, family-owned German corporation with companies in 34 countries all over the world. Founded in 1946, the corporation employs 2,000 people in Germany and 5,200 worldwide. In 2008, Grünenthal achieved revenues of about 864 million Euros.
Together with highly specialised partners we are pressing on with the research and development of new active substances. For this we are concentrating on selected indications and the latest technological developments. We are intensively searching for innovative ways of improving pain, pain relief and reducing side-effects.
Grünenthal is an independent, family-owned, research-based pharmaceutical company based in Aachen operating internationally. In 1948 Grünenthal was the first German company to manufacture and market penicillin. Today analgesics are our main competence. Beside this Grünenthal is active in the marketing of oral contraceptives and the treatment of respiratory tract diseases.
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
See our Cookie Privacy Policy Here
